Strong EUPATI Presence at Roadmap Initiative to Good Lay Summary Practices Meeting Having participated in a clinical trial in the past, I found it difficult to get access to the results in an understandable format. This is an issue for many patients who have either taken part in or would like to know the outcomes…Read more
Note: This webinar took place on 26 September 2017. You can find a video recording and the presentations used during the webinar below. Webinar introduction Increasingly, patient advocates take part in HTA processes across Europe, which is also encouraged by the recommendations of Health Technology Assessment International. This webinar discusses the experience of patient advocates in HTA…Read more
A very important result from the EUPATI project was the development, broad consultation and final release of guidances on the best approach to interaction of patients with pharmaceutical industry-led medicines R&D, regulatory authorities, ethics committees and HTA agencies. This webinar focuses on the Guidance on Patient Involvement in regulatory processes.
The European Patients’ Academy (EUPATI) guidance document on patient involvement in regulatory processes aims to support the integration of patient involvement across the entire process.
What is compassionate use? The term ‘compassionate use’ refers to special programmes set up to make unauthorised medicines available to patients. In particular, this may be a way of making a promising but not yet authorised medicine available to patients who: cannot currently be treated satisfactorily with authorised medicines, have a disease for which no…Read more
A falsified medicine is a fake that passes itself off as a real, authorised medicine but contains poor quality or falsified ingredients, no ingredients or in the wrong dose and pose a major threat to public health and patient safety.
Medicines regulation ensures that only sufficiently safe, effective and high quality medicines can be marketed.
To obtain clinical trial approval, a Clinical Trial Application must be submitted to regulatory bodies and a Research Ethics Committee who review the protocol and gives a positive or negative opinion. This is to ascertain that the research is conducted in compliance with European regulations, directives and guidelines defined by the International Conference on Harmonisation. This is an international quality standard that describes the responsibilities and expectations of all participants in the conduct of clinical trials, including investigators, monitors, sponsors and ethics committees.
The medicines development process’ ultimate goal is an approval for marketing the new medicinal product – a Marketing Authorisation. This should be an integral part of all steps throughout the life-cycle of the medicinal product. A Marketing Authorisation Application contains information on quality, and non-clinical and clinical studies.
A patients involved case report on the Duchenne Parent Project collaborating with academia and industry to find a cure/treatment for Duchenne Muscular Dystrophy.